Skip to Content

'
Jose A. Karam, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007 University of Texas Southwestern Medical Center, Dallas, TX, Graduate Certificate in Clinical Sciences, Clinical Sciences
2002 American University of Beirut, Beirut, Lebanon, MD, Medicine, with Distinction
1998 American University of Beirut, Beirut, Lebanon, BS, Biology, with Distinction

Postgraduate Training

7/2010-6/2011 Clinical Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2009-6/2010 Research Fellowship, Urologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2005-6/2009 Clinical Residency, Urology, University of Texas Southwestern Medical Center, Dalls, TX
7/2004-6/2005 Clinical Internship, General Surgery, University of Texas Southwestern Medical Center, Dallas, TX
2/2003-5/2004 Research Fellowship, Tumor Biology, University of Texas Southwestern Medical Center, Dallas, TX
10/2002-1/2003 Research Fellowship, Leukemia, American University of Beirut, Beirut, Lebanon

Board Certifications

3/2013 American Board of Urology

Experience/Service

Administrative Appointments/Responsibilities

Member, Cancer Education Committee - Genitourinary Cancer Track, American Society of Clinical Oncology (ASCO), Alexandria, VA, 6/2013-5/2016
Ex Officio Member, AACR Clinical and Translational Research Committee, Philadelphia, PA, 2010-2012
Associate Member Council, American Association of Cancer Research, Philadelphia, PA, 2008-2011

Institutional Committee Activities

Member, UT Southwestern Graduate Medical Education Council, 2006-2009

Honors and Awards

2013 Best Reviewer in 2013 Award, The Journal of Urology/American Urological Association
2013 Top Reviewer, British Journal of Urology International
2011 Reviewer Roll of Honors, British Journal of Urology International
2010 2010 Clinical Fellowship Award, University of Texas MD Anderson Cancer Center
2010 ASCO Foundation Merit Award, American Society of Clinical Oncology
2010 Travel Award, American Association of Cancer Research
2009 GlaxoSmithKline Outstanding Clinical Scholar Award, American Association of Cancer Research
2008 ASCO Foundation Merit Award, American Society of Clinical Oncology
2008 Poster Winner - Second place, Society of Urologic Oncology
2007 Novacea Gerald P. Murphy Scholar, American Urological Association
2007 Resident Essay Contest - Third Place, South Central Section of the American Urological Association
2007 Travel Award, American Urological Association
2006 Resident Essay Contest - Fifth place, American Urological Association
2006 Travel Award, American Urological Association
2003 Travel Award, American Association of Cancer Research
2003 Travel Award, American Urological Association
2003 Travel Award, American Urological Association
2002 Alpha Omega Alpha Honor Medical Society, Alpha Honor Medical Society
2002 Doctor of Medicine with Distinction, American University of Beirut
2000-2002 Dean's Honor List, American University of Beirut
1998 Bachelor of Sciences with Distinction, American University of Beirut
1996-1998 Dean's Honor List, American University of Beirut

Professional Memberships

Alpha Omega Alpha Honor Medical Society
Member, 8/2002-present
American Association of Cancer Research
Active Member, 2013-present
American Association of Clinical Urologists
Resident Member, 3/2006-present
American Society of Clinical Oncology
Full Member, 2013-present
American Urological Association
Candidate Member, 2005-present
Endourological Society
Member, 1/2009-present
Society for Basic Urologic Research
Member, 4/2003-present
Society of Surgical Oncology
Candidate Member, 3/2010-present
Society of Urologic Oncology
Candidate Member, 12/2009-present
South Central Section of the American Urological Association
Candidate Member, 10/2006-present
Texas Urological Association
Associate Member, 3/2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urol Oncol. e-Pub 4/4/2014. PMID: 24709415.
2. Karam JA, Wood CG, Compton ZR, Rao P, Vikram R, Ahrar K, Matin SF. Salvage Surgery After Energy Ablation For Renal Masses. BJU Int. e-Pub 3/24/2014. PMID: 24656119.
3. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. e-Pub 2/8/2014. PMID: 24518767.
4. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 Trial of Neoadjuvant Axitinib in Patients with Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma. Eur Urol. e-Pub 2/7/2014. PMID: 24560330.
5. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, Shariat SF, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. Eur Urol. e-Pub 12/25/2013. PMID: 24388440.
6. Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA, Wood CG. Positive vascular wall margins have minimal impact on cancer outcomes in non-metastatic RCC patients with tumor thrombus. BJU Int. e-Pub 10/15/2013. PMID: 24128265.
7. Faria EF, Caputo PA, Wood CG, Karam JA, Nogueras-González GM, Matin SF. Robotic partial nephrectomy shortens warm ischemia time, reducing suturing time kinetics even for an experienced laparoscopic surgeon: a comparative analysis. World J Urol. e-Pub 6/20/2013. PMID: 23783881.
8. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. e-Pub 3/19/2013. PMID: 23510233.
9. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. Eur Urol. e-Pub 2/9/2013. PMID: 23419322.
10. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM. Metabolism of Kidney Cancer: From the Lab to Clinical Practice. Eur Urol. e-Pub 9/2012. PMID: 23063455.
11. Abel EJ, Karam JA, Carrasco A, Matin SF. Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma. J Endourol 25(8):1323-7, 8/2011. e-Pub 7/20/2011. PMID: 21774667.
12. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am 25(4):753-64, 8/2011. PMID: 21763966.
13. Karam JA, Huang S, Fan J, Stanfield J, Schultz RA, Pong RC, Sun X, Mason RP, Xie XJ, Niu G, Chen X, Frenkel EP, Sagalowsky AI, Hsieh JT. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int J Cancer 128(12):2823-32, 6/15/2011. e-Pub 10/26/2010. PMCID: PMC3082622.
14. Cost NG, Delacroix SE, Sleeper JP, Smith PJ, Youssef RF, Chapin BF, Karam JA, Culp S, Abel EJ, Brugarolas J, Raj GV, Sagalowsky AI, Wood CG, Margulis V. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 59(6):912-8, 6/2011. e-Pub 2/23/2011. PMID: 21367518.
15. Karam JA, Ahrar K, Matin SF. Ablation of kidney tumors. Surg Oncol Clin N Am 20(2):341-53, viii, 4/2011. e-Pub 12/13/2010. PMID: 21377587.
16. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 59(4):619-28, 4/2011. e-Pub 12/8/2010. PMID: 21167632.
17. Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. e-Pub 3/22/2011. PMID: 21426474.
18. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2/2011. e-Pub 12/17/2010. PMID: 21167518.
19. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 11/2010. e-Pub 9/17/2010. PMID: 20846689.
20. Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep 2, 2010. e-Pub 6/23/2010. PMCID: PMC2950042.
21. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 15(22):7012-9, 11/15/2009. e-Pub 11/10/2009. PMID: 19903782.
22. Karam JA, Raj GV. Growing teratoma syndrome. Urology 74(4):783-4, 10/2009. e-Pub 8/3/2009. PMID: 19647298.
23. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 182(3):907-13, 9/2009. e-Pub 7/17/2009. PMID: 19616250.
24. Decker DB, Karam JA, Wilcox DT. Pediatric hemorrhagic cystitis. J Pediatr Urol 5(4):254-64, 8/2009. e-Pub 3/19/2009. PMID: 19303365.
25. Shariat SF, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. N Engl J Med 2007;356:2271-81. Eur Urol 55(1):250-2, 1/2009. PMID: 20050019.
26. Karam JA, Shariat SF, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. BJU Int 102(9 Pt B):1221-7, 11/2008. PMID: 19035885.
27. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, Shariat SF. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. Eur Urol 54(4):961-3, 10/2008. e-Pub 5/8/2008. PMID: 18485573.
28. Shariat SF, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. BJU Int 102(6):728-33; discussion 733, 9/2008. e-Pub 4/24/2008. PMID: 18435808.
29. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 14(12):3785-91, 6/15/2008. PMID: 18559597.
30. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 14(11):3362-6, 6/1/2008. PMID: 18519764.
31. Karam JA, Kabbani W, Sagalowsky AI. Pseudosarcomatous fibromyxoid tumor of the bladder. Urol Oncol 26(3):291-4, May-Jun, 5/2008. e-Pub 11/26/2007. PMID: 18452822.
32. Shariat SF, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. Biomark Med 2(2):165-80, 4/2008. PMID: 20477438.
33. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, Shariat SF. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 14(5):1418-22, 3/1/2008. PMID: 18316564.
34. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 101(6):675-83, 3/2008. e-Pub 10/17/2007. PMID: 17941930.
35. Fan J, Stanfield J, Guo Y, Karam JA, Frenkel E, Sun X, Hsieh JT. Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer. Clin Cancer Res 14(4):1200-7, 2/15/2008. PMID: 18281555.
36. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, Shariat SF. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. J Urol 179(2):478-84; discussion 484, 2/2008. PMID: 18076936.
37. Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 18(1):1-8, 1/2008. PMID: 18090481.
38. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 10(2):120-35, 2008. PMCID: PMC2483317.
39. Bensalah K, Lotan Y, Karam JA, Shariat SF.. New circulating biomarkers for prostate cancer. Prostate Cancer & Prostatic Dis. 11(2):112-120, 2008. PMID: 17998918.
40. Shariat SF, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Clin Cancer Res 13(18 Pt 1):5377-84, 9/15/2007. PMID: 17875766.
41. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 70(3):482-6, 9/2007. PMID: 17905101.
42. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13(15 Pt 1):4400-6, 8/1/2007. PMID: 17671122.
43. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 3(4):449-61, 8/2007. PMID: 17661720.
44. Karam JA, Vazquez DV, Lin VK, Zimmern PE. Elastin expression and elastic fibre width in the anterior vaginal wall of postmenopausal women with and without prolapse. BJU Int 100(2):346-50, 8/2007. e-Pub 5/26/2007. PMID: 17532852.
45. Karam JA, Baker LA. Focal orchitis presenting as bilateral testicular masses. J Pediatr Urol 3(4):337-9, 8/2007. e-Pub 12/12/2006. PMID: 18947769.
46. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate 67(6):614-22, 5/1/2007. PMID: 17299799.
47. Karam JA, Fan J, Stanfield J, Richer E, Benaim EA, Frenkel E, Antich P, Sagalowsky AI, Mason RP, Hsieh JT. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 120(8):1795-802, 4/15/2007. PMID: 17230511.
48. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8(2):128-36, 2/2007. PMID: 17267327.
49. Svatek RS, Karam JA, Rogers TE, Schulman, MS, Margulis V, Benaim EA.. Intraluminal crystalloids are highly associated with prostatic adenocarcinoma on concurrent biopsy specimens. Prostate Cancer & Prostatic Dis. 10(3):279-282, 2007. PMID: 17325718.
50. Chen H, Karam JA, Schultz R, Zhang Z, Duncan C, Hsieh JT. Cloning of mouse Dab2ip gene, a novel member of the RasGTPase-activating protein family and characterization of its regulatory region in prostate. DNA Cell Biol 25(4):232-45, 4/2006. PMID: 16629596.
51. Svatek R, Karakiewicz PI, Shulman M, Karam J, Perrotte P, Benaim E. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer. Eur Urol 49(4):666-74, 4/2006. e-Pub 1/6/2006. PMID: 16423446.
52. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 24(2):152-60, Mar-Apr, 3/2006. PMID: 16520279.
53. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48(3):424-31, 9/2005. PMID: 15963628.
54. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de The H, Hermine O, Bazarbachi A.. Efficacy and Mechanism of Action of the Proteasom Inhibitor PS-341 in T-Cell Lymphomas and HTLV-I Associated Adult T-Cell Leukemia/Lymphoma. Oncogene 13(24):419-430, 2005. PMID: 15543232.
55. Benaim EA, Karam JA, Soboorian MH, Roehrborn CG, McConnell JD, Lin V. The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate 60(4):310-6, 9/1/2004. PMID: 15264242.
56. Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 63(4):732-6, 4/2004. PMID: 15072890.
57. Karam JA, Baker LA. Images in clinical medicine. True hermaphroditism. N Engl J Med 350(4):393, 1/22/2004. PMID: 14736931.
58. Karam JA, Mason RP, Koeneman KS, Antich PP, Benaim EA, Hsieh JT. Molecular imaging in prostate cancer. J Cell Biochem 90(3):473-83, 10/15/2003. PMID: 14523981.

Invited Articles

1. Kim DY, Wood CG, Karam JA. Treating the Two Extremes in Renal Cell Carcinoma: Management of Small Renal Masses and Cytoreductive Nephrectomy in Metastatic Disease. ASCO Educational Book 2014. In Press.
2. Kim DY, Karam JA, Wood CG. Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. World J Urol. e-Pub 4/18/2014. PMID: 24744223.
3. Karam JA. Cautious Approach Advised Until Compelling Evidence for Cytoreductive Nephrectomy Emerges from Pivotal Trials. Kidney Cancer Journal 12(1):27-29, 2014.
4. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol. e-Pub 11/13/2013. PMID: 24239464.
5. Wood CG, Karam JA. Co-Clinical trials, using personalized tumor xenograft models, usher in a new paradigm to understand biology of RCC and response to treatment. Kidney Cancer Journal 10(3):70-76, 12/2012.
6. Karam JA, Wood CG. Management of Kidney Cancer with Tumor Thrombus. TTMed Urology, www.ttmed.com/urology, 2010.
7. Karam JA, Lotan Y, Shariat SF. Bladder Cancer Screening and Future Directions in Urine-Based Markers for Bladder Urothelial Carcinoma. Lab Medicine 38(2):116-120, 2007.
8. Karam JA, Lotan Y, Shariat SF. Urine Cytology and Commercially Available Urine-Based Markers for Monitoring of Bladder Urothelial Carcinoma. Lab Medicine 38(1):48-52, 2007.

Editorials

1. Karam JA, Wood CG. Re: Prognostic or Predictive Plasma Cytokines and Angiogenic Factors for Patients Treated with Pazopanib for Metastatic Renal-cell Cancer: A Retrospective Analysis of Phase 2 and Phase 3 Trials. Eur Urol 63(4):769, 4/2013. PMID: 23438394.
2. Karam JA, Wood CG. Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents: A Review. Urology 81(1):208, 1/2013.
3. Karam JA, Wood CG.. The Effects of Temporary Ischemia in Partial Nephrectomy on Renal Functional Outcomes: How Can Effects Best Be Estimated, and Can They Be Mitigated? Eur Urol 62(1):136-8, 7/2012. e-Pub 3/2012. PMID: 22410575.
4. Karam JA, Wood CG. Management of Small Renal Masses: Watch, Cut, Freeze, or Fry? Eur Urol 61(5):905-6, 5/2012. e-Pub 2/2012. PMID: 22310973.
5. Kenney PA, Karam JA. PERCUTANEOUS CRYOABLATION OF SOLITARY SPORADIC RENAL CELL CARCINOMAS. BJU Int. 5/2012. PMID: 22583351.
6. Kenney PA, Karam JA. Editorial Comment. J Urol, 2/2012. e-Pub 12/2012. PMID: 22177914.
7. Kenney PA, Karam JA. HIGHER PERIOPERATIVE MORBIDITY AND IN-HOSPITAL MORTALITY IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING NEPHRECTOMY FOR NON-METASTATIC KIDNEY CANCER: A POPULATION-BASED ANALYSIS. BJU Int. 2/2012. PMID: 22321381.
8. Karam JA. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int 108(4):537-8, 8/2011. e-Pub 3/3/2011. PMID: 21371243.
9. Karam JA, Wood CG. The dark side of targeted therapy. Eur Urol 59(4):541-2, 4/2011. e-Pub 2/1/2011. PMID: 21295398.
10. Karam JA, Wood CG. Editorial comment. J Urol 183(3):870; discussion 870, 3/2010. e-Pub 1/18/2010. PMID: 20083268.
11. Karam JA, Sagalowsky AI. Minimally invasive radical cystectomy for bladder cancer? Lancet Oncol 9(4):317-8, 4/2008. PMID: 18374289.
12. Hsieh JT, Karam JA, Min W. Genetic and biologic evidence that implicates a gene in aggressive prostate cancer. J Natl Cancer Inst 99(24):1823-4, 12/19/2007. e-Pub 12/11/2007. PMID: 18073373.

Book Chapters

1. Merrill MM, Karam JA. Renal Cancer: Contemporary Management. In: Post-Operative Surveillance Protocols, 2012.
2. Karam JA, Wood CG. Genitourinary Cancer. In: M. D. Anderson Surgical Oncology Handbook, 5th. Lippincott Williams & Wilkins, 920, 2011.
3. Karam JA, Wood CG. Surgical Management of Metastatic/Advanced Kidney Cancer. In: Comprehensive Textbook of Genitourinary Oncology, 4th. Lippincott Williams & Wilkins, 973, 2011.
4. Karam, JA, Hsieh JT. Anti-Cancer strategy of transitional cell carcinoma of bladder based on induction of different types of programmed cell deats. In: Apoptosis in Carcinogenesis and Chemotherapy. Springer, 25-50, 2009.
5. Karam JA, Benaim EA, Chen H, Pong RC, Hsieh JT. Epigenetics in prostate cancer. In: Prostate Cancer: Basic mechanisms and therapeutic approaches. World Scientific Publishing Co: New Jersey, 213-228, 2005.

Last updated: 4/18/2014